Two-Sample UCH-L1 and GFAP Testing for Hyperacute TBI Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing traumatic brain injury (TBI), particularly mild TBI, lack objective and accurate measurements, relying heavily on subjective data and inadequate tools like head CT and Glasgow Coma Score, which are not sensitive to subtle pathologies and result in inappropriate patient classification and therapeutic trials.
Innovation Solution
A method involving an assay on two samples taken from a subject within 2-6 hours post-injury to detect a combination of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) biomarkers, allowing differentiation between mild, moderate, severe, and moderate to severe TBIs based on biomarker level changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If head CT is used for TBI evaluation, then structural abnormalities can be detected, but it is expensive, exposes patients to unnecessary radiation, and is unrevealing for the vast majority of mild TBI cases
Solution Approach 1:
The patent replaces the mechanical imaging system (head CT) with a biochemical detection system that measures biomarker levels (UCH-L1 and GFAP) in blood samples. This substitution eliminates radiation exposure while providing sensitive detection of TBI, particularly for mild cases where CT is unrevealing.
Solution Approach 2:
The patent introduces blood biomarkers (UCH-L1 and GFAP) as intermediary substances that indirectly indicate TBI severity. These biomarkers serve as mediators between the brain injury and the diagnostic test, allowing detection of TBI without direct brain imaging and thus avoiding radiation exposure.
2Ease of operation
If Glasgow Coma Score is used for TBI assessment, then acute severity can be related, but it is based on subjective data and is not sensitive for subtle pathology
Solution Approach 1:
The patent replaces the subjective clinical assessment system (Glasgow Coma Score) with an objective biochemical measurement system. By measuring biomarker levels in blood, the system provides quantitative, objective data that is both simple to obtain and highly sensitive for detecting TBI, including subtle pathologies.
Solution Approach 2:
The patent enables the body to provide its own diagnostic information through biomarkers that are naturally produced in response to TBI. The biomarkers self-indicate the presence and severity of injury without requiring complex clinical evaluation, making the system both simple and accurate.
3Adaptability or versatility
If current TBI algorithms are used for patient classification, then acute severity can be grouped, but patients are classified into heterogeneous groups that undermine clinical trial integrity
Solution Approach 1:
The patent segments the heterogeneous TBI population into distinct subgroups based on biomarker levels (UCH-L1 and GFAP). This segmentation creates homogeneous groups with similar injury characteristics, enabling reliable stratification for clinical trials while maintaining the versatility to handle different TBI severities.
Solution Approach 2:
The patent changes the classification parameter from subjective clinical scores to objective biomarker concentrations. By using quantitative biomarker levels as the classification parameter, the system achieves both reliable patient stratification for trial integrity and the versatility to accommodate different injury types and severities.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.